AmBisome® has improved fungicidal activity against the most clinically important yeasts and moulds vs. echinocandins and azoles.2,4,6
Fungicidal activity is particularly important for immunocompromised patients, as their immune systems may not be able to eliminate fungal pathogens alongside a fungistatic agent.7
Use the tabs below to discover more about the activity of different types of antifungal therapy
AmBisome® has a broad spectrum of activity against most fungal pathogens, including those causing rare and difficult to treat infections.2-5
Scroll down to discover more about the life-threatening IFIs caused by both common and rare fungal pathogens
In a non-inferiority study (n=531), AmBisome® (3 mg/kg/day) demonstrated efficacy as a 1st-line therapy for proven invasive candidiasis (IC) or candidaemia in patients with a variety of underlying conditions, including haematological disorders and neutropenia.*
Fungal infection was considered to contribute to the cause of death in 9% and 13% of patients in the AmBisome® (n=25) and micafungin (n=34) groups, respectively (p=0.22).10
In a 2007 study, a retrospective analysis found that after 12 weeks the rate of survival in patients with proven (microbiological-confirmed) or probable (based solely on the presence of a halo sign) invasive aspergillosis (IA) treated with AmBisome® (3 mg/kg/day) (n=107) was 72%.†11
Keep scrolling to discover how AmBisome® can help combat the emerging threat of rare and difficult-to-treat infections
In a prospective, multicentre pilot study for the treatment of proven or probable mucormycosis, a combination of high-dose AmBisome® (10 mg/kg/day) and surgery was associated with an overall response rate of 36% (12/33 patients) at week 4 and 45% (14/31 patients) at week 12.‡12
In a retrospective study (n=70), the timely initiation (within 6 days of diagnosis) of amphotericin B, the active ingredient in AmBisome®, significantly reduced mortality in patients with haematologic malignancies with definite or probable mucormycosis vs. delayed treatment.¶13
AmBisome® is a treatment of choice for central nervous system (CNS) histoplasmosis, with demonstrated improved survival (10.6 months) for patients compared with amphotericin B lipid complex (8.3 months) (p=0.040).17
In a comparison between two separate closed clinical trials, AmBisome® (3 mg/kg/day) was found to clear the fungal burden of disseminated histoplasmosis in patients with AIDS faster than itraconazole.15
Stay one step ahead of IFIs in your at-risk patients with AmBisome®'s broad-spectrum fungicidal activity and proven clinical efficacy1,2,4,6,8,10,11,15-19
AIDS: Acquired immune deficiency syndrome; ART: Antiretroviral therapy; EORTC/MSG: European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; HIV: Human immunodeficiency virus; IA: Invasive aspergillosis; IC: Invasive candidaemia; ITT: Intention-to-treat; WHO: World Health Organisation.
Job code: IHQ-AMB-0526
Date of Preparation: April 2022